Endo Int'l (ENDP) Tops Q4 EPS by 4c; Guides FY15 EPS, Revs Below Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. CRWD
5. DOX
6. VRTX
7. CHKP
8. ON
9. INSP
10. CVI

Go back to Endo Int'l (ENDP) Tops Q4 EPS by 4c; Guides FY15 EPS, Revs Below Expectations

Endo Pharmaceuticals (ENDP) Target Lifted to $100 at Guggenheim

March 2, 2015 3:19 PM EST

Guggenheim analyst Swati Kumar reiterated a Buy rating and boosted its price target on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) to $100.00 (from $80.00) after the the company announced Q4 results and the sale of its men's health and prostate health business for $1.65B to Boston... More

Boston Scientific (BSX) to Acquire Endo's AMS Urology Portfolio in $1.65B Deal

March 2, 2015 7:02 AM EST

Endo Int'l (NASDAQ: ENDP) announced it has entered into a definitive agreement with Boston Scientific (NYSE: BSX), under which Boston Scientific will acquire Endo's American Medical Systems' (AMS) Men's and Prostate Health businesses for up to $1.65 billion, with $1.6 billion in cash payable at closing. Endo is also eligible to receive a potential milestone payment of $50 million in cash conditioned on Boston Scientific achieving certain product revenue... More